Duligotumab

Duligotumab is a monoclonal antibody designed for the treatment of cancer. It is one of the many therapeutic antibodies that have been developed in the field of oncology to target and destroy cancer cells.

Mechanism of Action

Duligotumab works by binding to a specific target on the surface of cancer cells. This target is a protein that is overexpressed in many types of cancer, making it an ideal target for therapy. Once duligotumab binds to this target, it triggers an immune response that leads to the destruction of the cancer cell.

Clinical Trials

Duligotumab has been tested in several clinical trials to determine its safety and efficacy in treating various types of cancer. These trials have shown promising results, with many patients experiencing a reduction in tumor size and improved survival rates. However, like all drugs, duligotumab has potential side effects, which can include fatigue, nausea, and decreased appetite.

Future Directions

Research is ongoing to further understand the potential of duligotumab in cancer treatment. Scientists are also exploring the possibility of combining duligotumab with other therapies to enhance its effectiveness.

See Also

• Monoclonal antibodies in oncology
• Cancer immunotherapy
• Clinical trials

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian